Deutsch English Français

Contact

EP1253942

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1253942

EP1253942 - CD40-BINDING APC-ACTIVATING MOLECULES [Right-click to bookmark this link]
Status	The application has been refused Status updated on 31.07.2009 Database last updated on 20.05.2024
Most recent event Tooltip	31.07.2009	Refusal of application	published on 02.09.2009 [2009/36]
Applicant(s)	For all designated states PanGenetics B.V. Yalelaan 46 3584 CM Utrecht / NL
	[2006/33]
Former [2002/45]	For all designated states Tanox, Inc. 10301 Stella Link Houston, TX 77025 / US
Inventor(s)	01 / THOMAS, David 1920 Albans Rd. Houston, TX 77005 / US
	02 / DE BOER, Mark Naarderweg 20 NL-1261 BT Blaricum / NL
	03 / RES, Pieter, C., J., M. Bloemveldlaan 49 NL-2015 HC Haarlem / NL
	04 / SIMONS, Peter, J. Leidsestraat 43 NL-2182 DH Hillegom / NL
	[2002/45]
Representative(s)	Prins, Adrianus Willem, et al V.O. Johan de Wittlaan 7 2517 JR Den Haag / NL
	[N/P]
Former [2004/11]	Prins, Adrianus Willem, et al Vereenigde, Nieuwe Parklaan 97 2587 BN Den Haag / NL
Former [2003/30]	Bot, David Simon Maria, et al Nederlandsch Octrooibureau Scheveningseweg 82 P.O.Box 29720 2502 LS Den Haag / NL
Former [2002/45]	VOSSIUS & PARTNER Siebertstrasse 4 81675 München / DE
Application number, filing date	01908789.9	01.02.2001
	[2002/45]
	WO2001US03378
Priority number, date	US20000178934P	01.02.2000 Original published format: US 178934 P
	[2002/45]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO0156603
	Date:	09.08.2001
	Language:	EN
	[2001/32]
	Type:	A1 Application with search report
	No.:	EP1253942
	Date:	06.11.2002
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.08.2001 takes the place of the publication of the European patent application.
	[2002/45]
Search report(s)	International search report - published on:	US	09.08.2001
	(Supplementary) European search report - dispatched on:	EP	03.05.2004
Classification	IPC:	C07K16/28, A61K39/395, C07K16/00, C12N5/10, C12N15/00, C12N5/12, C12N15/13, C12N15/63	[2004/24]
	CPC:	A61K39/39541 (EP,US); A61P35/00 (EP); A61P37/02 (EP); C07K16/2818 (EP,US); C07K16/2878 (EP,US); A61K2039/505 (EP,US); (+) A61K38/00 (EP,US); C07K2317/31 (EP,US) (-)
	C-Set:	A61K39/39541, A61K2300/00 (EP,US)
	Former IPC [2002/45]	A61K39/395, C07K16/00, C07K16/28, C12N5/10, C12N5/12, C12N15/00, C12N15/11, C12N15/13, C12N15/12, C12N15/63
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2002/45]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	CD40-BINDENDE UND APC-AKTIVIERENDE MOLEKÜLE	[2002/45]
	English:	CD40-BINDING APC-ACTIVATING MOLECULES	[2002/45]
	French:	MOLECULES D'ACTIVATION DES APC SE LIANT AU CD40	[2002/45]
Entry into regional phase	22.08.2002	National basic fee paid
	22.08.2002	Search fee paid
	22.08.2002	Designation fee(s) paid
	22.08.2002	Examination fee paid
Examination procedure	23.08.2001	Request for preliminary examination filed International Preliminary Examining Authority: US
	22.08.2002	Examination requested [2002/45]
	26.04.2006	Despatch of a communication from the examining division (Time limit: M04)
	31.07.2006	Reply to a communication from the examining division
	29.05.2008	Date of oral proceedings
	10.07.2008	Despatch of communication that the application is refused, reason: substantive examination [2009/36]
	10.07.2008	Minutes of oral proceedings despatched
	26.07.2009	Application refused, date of legal effect [2009/36]
Appeal following examination	09.09.2008	Appeal received No. T0031/09
	01.07.2009	Result of appeal procedure: appeal of the applicant inadmissible
Divisional application(s)	EP08157131.7 / EP1975182
Fees paid	Renewal fee
	28.02.2003	Renewal fee patent year 03
	05.12.2003	Renewal fee patent year 04
	15.02.2005	Renewal fee patent year 05
	15.02.2006	Renewal fee patent year 06
	15.02.2007	Renewal fee patent year 07
	15.02.2008	Renewal fee patent year 08
	17.03.2008	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO9961065 (UNIV LEIDEN MEDICAL CT [NL], et al) [X] 1-9,12-20 * page 9, line 12 - page 15, line 2 * * page 18, line 15 - page 19, line 18; claims 1-3,8 *;
		[A]WO9961057 (TANOX INC [US]) [A] 10,11 * abstract *;
		[X] - CHALLA A ET AL, "Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells", ALLERGY (COPENHAGEN), (199906), vol. 54, no. 6, ISSN 0105-4538, pages 576 - 583, XP002276806 [X] 1-9,12-20 * abstract * * page 582, column L, line 11 - column R, line 15 * DOI: http://dx.doi.org/10.1034/j.1398-9995.1999.00092.x
		[X] - LEDBETTER J A ET AL, "Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5", CRITICAL REVIEWS IN IMMUNOLOGY, CRC PRESS, INC, XX, (1997), vol. 17, no. 5-6, ISSN 1040-8401, pages 427 - 435, XP002954466 [X] 1-9,12-20 * abstract *
		[X] - DULLFORCE P ET AL, "ENHANCEMENT OF T CELL-INDEPENDENT IMMUNE REPSONSES IN VIVO BY CD40 ANTIBODIES", NATURE MEDICINE, NATURE PUBLISHING, CO, US, (199801), vol. 4, no. 1, ISSN 1078-8956, pages 88 - 91, XP009026323 [X] 1-9,12-20 * abstract * DOI: http://dx.doi.org/10.1038/nm0198-088
		[X] - ZHOU Z-H ET AL, "An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, (1999), vol. 18, no. 6, ISSN 0272-457X, pages 471 - 478, XP002954467 [X] 1-9,12-20 * abstract *
		[X] - BJORCK P ET AL, "CD40 ANTIBODIES DEFINING DISTINCT EPITOPES DISPLAY QUALITATIVE DIFFERENCES IN THERI INDUCTION OF B-CELL DIFFERENTIATION", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, (1996), vol. 87, ISSN 0019-2805, pages 291 - 295, XP002930984 [X] 1-9,12-20 * abstract * DOI: http://dx.doi.org/10.1046/j.1365-2567.1996.428508.x
		[X] - FRENCH R ET AL, "CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help", NATURE MEDICINE, NATURE PUBLISHING, CO, US, (199905), vol. 5, no. 5, ISSN 1078-8956, pages 548 - 553, XP002159390 [X] 1-9,12-20 * abstract * DOI: http://dx.doi.org/10.1038/8426
	International search	[Y]US5534254 (HUSTON JAMES S [US], et al)
		[X] - SCHWABE ET AL., "Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies", HYDRIDOMA, (1997), vol. 16, no. 3, pages 217 - 226, XP002940165

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p